Regeneron Pharmaceuticals Inc. closed 49.58% below its 52-week high of $1,211.20, which the company achieved on August 27th.

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss ...

Long Island's six Regeneron Science Talent Search finalists are not yet out of high school and already, they've worked in some of the country's leading laboratories, helped to advance scientific ...

This was the stock's second consecutive day of losses.